Christian Späth1, Christoph Busemann, William H Krüger. 1. Department of Internal Medicine C - Haematology and Oncology, Marrow Transplantation, and Palliative Care, Ernst-Moritz-Arndt-University Greifswald, Ferdinand-Sauerbruch-Str., 17475, Greifswald, Germany.
Abstract
INTRODUCTION: Allogeneic stem cell transplantation (alloSCT) has become available for elderly patients or for patients with comorbidities by introduction of reduced-intense conditioning. Comorbidity-related prognosis after alloSCT can be estimated by the hematopoietic cell transplantation comorbidity index (HCT-CI). MATERIAL AND METHODS: The charts from 85 patients who have undergone 90 alloSCTs between 1999 and 2011 were analysed. Most patients received a dose-reduced conditioning and a graft from an unrelated donor. Patients were stratified for age, HCT-CI, cGvHD versus no cGvHD, and a modified HCT-CI with a further split high-risk score. RESULTS: Age over 60 years did not affect the outcome. Manifestation of cGvHD improved the prognosis significantly. An additional stratification of the high-risk group of the HCT-CI revealed that even a fraction of these patients can have considerable benefit from an alloSCT. Furthermore, this high-risk collective could be clearly discriminated into two groups with different outcomes. CONCLUSIONS: The investigation confirms that age is no absolute risk factor for alloSCT and demonstrates the heterogeneity of the high-risk group of the HCT-CI. A comprehensive investigation of an additional stratification is suggested. Furthermore, the authors encourage early withdrawal of immunosuppression, even in elderly patients and patients with comorbidities to permit graft-versus-leukaemia/lymphoma, since cGvHD is associated with a significantly better prognosis.
INTRODUCTION: Allogeneic stem cell transplantation (alloSCT) has become available for elderly patients or for patients with comorbidities by introduction of reduced-intense conditioning. Comorbidity-related prognosis after alloSCT can be estimated by the hematopoietic cell transplantation comorbidity index (HCT-CI). MATERIAL AND METHODS: The charts from 85 patients who have undergone 90 alloSCTs between 1999 and 2011 were analysed. Most patients received a dose-reduced conditioning and a graft from an unrelated donor. Patients were stratified for age, HCT-CI, cGvHD versus no cGvHD, and a modified HCT-CI with a further split high-risk score. RESULTS: Age over 60 years did not affect the outcome. Manifestation of cGvHD improved the prognosis significantly. An additional stratification of the high-risk group of the HCT-CI revealed that even a fraction of these patients can have considerable benefit from an alloSCT. Furthermore, this high-risk collective could be clearly discriminated into two groups with different outcomes. CONCLUSIONS: The investigation confirms that age is no absolute risk factor for alloSCT and demonstrates the heterogeneity of the high-risk group of the HCT-CI. A comprehensive investigation of an additional stratification is suggested. Furthermore, the authors encourage early withdrawal of immunosuppression, even in elderly patients and patients with comorbidities to permit graft-versus-leukaemia/lymphoma, since cGvHD is associated with a significantly better prognosis.
Authors: Mohamed L Sorror; Sergio Giralt; Brenda M Sandmaier; Marcos De Lima; Munir Shahjahan; David G Maloney; H Joachim Deeg; Frederick R Appelbaum; Barry Storer; Rainer Storb Journal: Blood Date: 2007-09-14 Impact factor: 22.113
Authors: F Ferrara; F Morabito; R Latagliata; B Martino; M Annunziata; E Oliva; E M Schiavone; F Pollio; S Palmieri; G Gianfaldoni; F Leoni Journal: Haematologica Date: 2001-08 Impact factor: 9.941
Authors: Herschel Wallen; Theodore A Gooley; H Joachim Deeg; John M Pagel; Oliver W Press; Frederick R Appelbaum; Rainer Storb; Ajay K Gopal Journal: J Clin Oncol Date: 2005-04-11 Impact factor: 44.544
Authors: A R Zander; C Berger; N Kröger; M Stockshläder; W Krüger; M Horstmann; J Grimm; W Zeller; H Kabisch; R Erttmann; P Schönrock; R Kuse; D Braumann; H J Illiger; W Fiedler; M de Witt; K D Hossfeld; H J Weh Journal: Clin Cancer Res Date: 1997-12 Impact factor: 12.531
Authors: Stephanie J Lee; John P Klein; A John Barrett; Olle Ringden; Joseph H Antin; Jean-Yves Cahn; Matthew H Carabasi; Robert Peter Gale; Sergio Giralt; Gregory A Hale; Osman Ilhan; Philip L McCarthy; Gerard Socie; Leo F Verdonck; Daniel J Weisdorf; Mary M Horowitz Journal: Blood Date: 2002-07-15 Impact factor: 22.113
Authors: Christoph Busemann; Andreas Jülich; Britta Buchhold; Vanessa Schmidt; Laila Schneidewind; Daniel Pink; Christian Andreas Schmidt; Thomas Neumann; William H Krüger Journal: J Cancer Res Clin Oncol Date: 2017-05-27 Impact factor: 4.553